The PRISM clinical trial assesses 4D-150 (4D Molecular Therapeutics) in adults with neovascular age-related macular degeneration, also known as wet AMD.
At the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting, Christine Kay, MD, of Vitreoretinal Associates in Gainesville, Florida, shared an update from the PRISM clinical trial. Dr. Kay is a vitreoretinal surgeon and inherited retinal disease specialist. She is actively involved as an investigator in multiple clinical trials at Vitreo Retinal Associates, and presented data on behalf of 4D Molecular Therapeutics (4DMT).
"The PRISM trial is a phase 1/2 clinical trial, looking at a gene therapy for wet [neovascular] macular degeneration," Dr. Kay said. "The 4D-150 vector is designed for intravitreal injection, single delivery, and it is optimized for intravitreal injection with specific retinal tropism, meaning increased transduction to retinal cells. It's also optimized to be able to invade the vitreoretinal barricades. The 4D-150 cassette is a dual vector, dual transgene cassette encoding both aflibercept as well as a micro-mRNA sequence inhibiting VEGF-C."
Dr. Kay provided an interim update on the phase 2b population extension study, which examined patients with severe disease and more recently-diagnosed patients who had seen less progression. To learn more, watch the full video and hear Dr. Kay's full summary of the results, including her analysis of the reduction in treatment burden.
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
2 Commerce Drive
Cranbury, NJ 08512